161 related articles for article (PubMed ID: 15672756)
1. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs.
Yamamoto T; Hagima N; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
Xenobiotica; 2004 Jul; 34(7):687-703. PubMed ID: 15672756
[TBL] [Abstract][Full Text] [Related]
2. Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models.
Yamamoto T; Itoga H; Kohno Y; Nagata K; Yamazoe Y
Xenobiotica; 2005 Jun; 35(6):627-46. PubMed ID: 16192112
[TBL] [Abstract][Full Text] [Related]
3. Differences in cytochrome P450 forms involved in the metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a novel sigma ligand, in human liver and intestine.
Yamamoto T; Hagima N; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
Drug Metab Dispos; 2003 Jan; 31(1):60-6. PubMed ID: 12485954
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenyl-ethoxy)-phenyl]-ethyl-amine-monohydrochloride (NE-100), a novel sigma ligand: contribution of cytochrome P450 forms involved in the formation of individual metabolites in human liver and small intestine.
Yamamoto T; Hagima N; Fukasawa M; Yamaguchi J; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
Drug Metab Pharmacokinet; 2003; 18(3):173-85. PubMed ID: 15618733
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
6. Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model.
Yamamoto T; Suzuki A; Kohno Y; Nagata K; Yamazoe Y
Curr Drug Metab; 2006 Feb; 7(2):135-46. PubMed ID: 16472104
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
9. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
[TBL] [Abstract][Full Text] [Related]
10. Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.
T'jollyn H; Snoeys J; Van Bocxlaer J; De Bock L; Annaert P; Van Peer A; Allegaert K; Mannens G; Vermeulen A; Boussery K
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):537-543. PubMed ID: 27317395
[TBL] [Abstract][Full Text] [Related]
11. CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement.
Somogyi AA; Menelaou A; Fullston SV
Xenobiotica; 2004 Oct; 34(10):875-87. PubMed ID: 15764408
[TBL] [Abstract][Full Text] [Related]
12. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.
Kirkwood LC; Nation RL; Somogyi AA
Br J Clin Pharmacol; 1997 Dec; 44(6):549-55. PubMed ID: 9431830
[TBL] [Abstract][Full Text] [Related]
14. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
[TBL] [Abstract][Full Text] [Related]
16. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.
Okubo M; Murayama N; Miura J; Chiba Y; Yamazaki H
Biochem Pharmacol; 2015 Jan; 93(1):104-9. PubMed ID: 25475885
[TBL] [Abstract][Full Text] [Related]
17. High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes.
Yamamoto T; Suzuki A; Kohno Y
Xenobiotica; 2003 Aug; 33(8):823-39. PubMed ID: 12936703
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
[TBL] [Abstract][Full Text] [Related]
19. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
20. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
